Cytokinetics (NASDAQ:CYTK) Stock Price Down 7.7% After Earnings Miss

Cytokinetics, Incorporated (NASDAQ:CYTK) fell 7.7% on Wednesday following a weaker than expected earnings announcement. The company traded as low as $64.51 and last traded at $64.6990. 667,422 shares were traded during trading, a decline of 61% from the average session volume of 1,698,679 shares. The stock had previously closed at $70.10.

The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. During the same period last year, the firm earned ($1.26) EPS. The business’s revenue was up 4.9% compared to the same quarter last year.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: MYQORZO approved in U.S., China and Europe; U.S. launch underway with first prescriptions dispensed within days — this turns near-term revenue into a tangible commercial story and is the biggest immediate catalyst. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue materially exceeded expectations: Q4 revenue ~$17.7M vs. consensus near $8M — suggests early commercial uptake or other revenue sources are ahead of models. Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Strong balance sheet: company reported ~ $1.2 billion in cash, cash equivalents and investments as of 12/31/25 and provided 2026 financial guidance — gives runway to support commercialization and ongoing trials. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Near-term clinical catalyst: company expects to share ACACIA‑HCM topline results in Q2 2026 — a positive binary event that could drive further re-rating if favorable. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst views are mixed on CYTK’s near-term outlook — some focus on commercial upside while others remain cautious on uptake and margins. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK) and Tandem Diabetes Care (TNDM)
• Neutral Sentiment: Full earnings and call transcripts are available for details on commercialization plans and cost structure; useful for investors who want management tone and phasing. Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Small EPS miss and widening loss: GAAP EPS was -$1.50 vs. consensus -$1.48, and the loss increased versus prior year (-$1.26) — ongoing operating losses remain a drag until revenue scales. Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a research note on Monday, December 22nd. The Goldman Sachs Group set a $95.00 price target on shares of Cytokinetics and gave the company a “buy” rating in a research report on Thursday, December 18th. B. Riley Financial lifted their price target on shares of Cytokinetics from $90.00 to $108.00 and gave the stock a “buy” rating in a report on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. lifted their target price on Cytokinetics from $70.00 to $74.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Sixteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $88.78.

Insider Activity

In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,200 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total transaction of $134,728.00. Following the transaction, the executive vice president directly owned 138,552 shares in the company, valued at approximately $8,484,924.48. This represents a 1.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Andrew Callos sold 52,486 shares of Cytokinetics stock in a transaction on Friday, December 5th. The shares were sold at an average price of $65.95, for a total transaction of $3,461,451.70. Following the completion of the sale, the executive vice president owned 50,660 shares of the company’s stock, valued at $3,341,027. This represents a 50.89% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 151,385 shares of company stock worth $9,817,158. Company insiders own 3.40% of the company’s stock.

Hedge Funds Weigh In On Cytokinetics

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Cytokinetics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock worth $765,538,000 after purchasing an additional 191,336 shares in the last quarter. State Street Corp raised its stake in Cytokinetics by 3.7% during the 4th quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock worth $370,139,000 after buying an additional 207,961 shares during the period. Deep Track Capital LP boosted its holdings in Cytokinetics by 17.8% in the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after acquiring an additional 650,000 shares in the last quarter. Geode Capital Management LLC grew its stake in Cytokinetics by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock valued at $194,214,000 after acquiring an additional 15,815 shares during the period. Finally, Vestal Point Capital LP increased its holdings in shares of Cytokinetics by 14.8% during the second quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock valued at $98,294,000 after acquiring an additional 384,469 shares in the last quarter.

Cytokinetics Stock Down 9.0%

The business has a 50-day moving average price of $64.14 and a two-hundred day moving average price of $58.32. The company has a market capitalization of $7.80 billion, a price-to-earnings ratio of -10.19 and a beta of 0.54.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.